Analysts Set Immunome, Inc. (NASDAQ:IMNM) Price Target at $29.80

Immunome, Inc. (NASDAQ:IMNMGet Free Report) has earned an average recommendation of “Buy” from the seven brokerages that are presently covering the company, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $29.80.

Several brokerages recently weighed in on IMNM. Guggenheim began coverage on Immunome in a research note on Monday, April 15th. They set a “buy” rating and a $35.00 target price for the company. Wedbush restated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research report on Tuesday, May 14th. JPMorgan Chase & Co. started coverage on shares of Immunome in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 price objective on the stock. Finally, Piper Sandler began coverage on shares of Immunome in a research note on Friday, May 31st. They set an “overweight” rating and a $27.00 target price for the company.

Read Our Latest Stock Analysis on Immunome

Immunome Price Performance

Immunome stock opened at $15.15 on Tuesday. Immunome has a 12-month low of $4.50 and a 12-month high of $30.96. The stock has a market capitalization of $908.55 million, a PE ratio of -2.01 and a beta of 1.85. The firm has a 50 day simple moving average of $16.39 and a 200-day simple moving average of $16.35.

Immunome (NASDAQ:IMNMGet Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.46. Immunome had a negative return on equity of 37.33% and a negative net margin of 1,829.44%. The firm had revenue of $1.03 million during the quarter, compared to analyst estimates of $4.00 million. On average, analysts forecast that Immunome will post -1.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jean Jacques Bienaime acquired 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The stock was purchased at an average price of $13.57 per share, with a total value of $27,140.00. Following the purchase, the director now owns 9,615 shares of the company’s stock, valued at approximately $130,475.55. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

Several hedge funds have recently bought and sold shares of the business. Redmile Group LLC grew its stake in Immunome by 26.0% during the 1st quarter. Redmile Group LLC now owns 4,889,554 shares of the company’s stock valued at $120,674,000 after acquiring an additional 1,010,139 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Immunome by 113.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock valued at $55,425,000 after purchasing an additional 1,194,451 shares in the last quarter. Vanguard Group Inc. grew its position in Immunome by 16.1% during the first quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock valued at $49,847,000 after purchasing an additional 279,712 shares in the last quarter. Janus Henderson Group PLC increased its stake in Immunome by 10.6% in the 1st quarter. Janus Henderson Group PLC now owns 1,538,414 shares of the company’s stock valued at $37,957,000 after buying an additional 146,943 shares during the period. Finally, Avidity Partners Management LP purchased a new stake in Immunome in the 4th quarter worth approximately $14,268,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Company Profile

(Get Free Report

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

Further Reading

Analyst Recommendations for Immunome (NASDAQ:IMNM)

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.